1. Home
  2. Food And Beverages
  3. Chemotherapy Induced Peripheral Neuropathy Market

Chemotherapy Induced Peripheral Neuropathy Market

Chemotherapy Induced Peripheral Neuropathy Size and Forecast (2025 - 2032), By Drug Class (Antidepressants, Anticonvulsants, Opioids, Others), By Indication (Platinum-based Agents, Taxanes, Vinca Alkaloids, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End-User (Hospitals, Specialty Clinics, Homecare Settings), and Geography.

Report Code: FOO00457
Report Format: PDF + PPT + Excel
Download PDF Buy Now
Report Description

Market Overview

The global Chemotherapy Induced Peripheral Neuropathy (CIPN) market is projected to grow at a CAGR of 4.8% from 2025 to 2032, reaching USD 2.3 billion by 2032 from USD 1.5 billion in 2022. North America is expected to dominate the market throughout the forecast period.

The CIPN market is clearly expanding in response to the rising cancer incidence and accompanying rise in chemotherapy treatments. As cancer survival rates rise, increasing focus is on managing side effects related to treatment including CIPN. Moreover influencing the market are ongoing research on new medicines and increasing adoption of combo therapy to effectively reduce CIPN symptoms.

 

Market Dynamics

Market Trend: Turning increasingly toward tailored medical approaches

Recent advances in genes and biomarker research are enabling more targeted CIPN therapy. Better outcomes and reduced side effects arise from healthcare providers personalizing therapies depending on particular patient characteristics and risk factors.

Market Driver: Improving knowledge and early CIPN diagnosis

Medical professionals increasingly find early identification and management of CIPN to be vital. Early intervention made feasible by improved screening tools and diagnostic techniques can significantly affect patient outcomes and quality of life. This trend is driving demand for supporting care decisions and CIPN treatments.

Market Restraint: Inadequate consistent treatment recommendations

Though much is still to learn, perspectives on perfect treatment strategies for CIPN remain varied. Creating consistent treatment strategies is challenging considering the variety of the disease and different patient responses to different treatments. This confusion might lead to several treatment strategies and uncertainty among medical experts on applying new therapies.

 

Segment Overview

Antidepressants, particularly duloxetine, are typically advised as first-line therapies and have been proven to successfully reduce CIPN symptoms in 60–70% of patients. Around 35% of antidepressant prescriptions for CIPN are written for the leading drug, duloxetine, whose sales are expected to reach $1.2 billion in 2023 for this indication alone. Clinical research has shown that in CIPN patients, duloxetine can lower pain levels by an average of 2.5 points on a 10-point scale. 

In comparison to monotherapy, combining antidepressants with additional medications can enhance symptom control by up to 40%, according to recent study including over 5,000 patients across 15 randomised trials. Antidepressants are becoming more and more common in CIPN care; in the last year, thirty percent of oncologists have embraced this combo strategy. 

 

Regional Outlook

A high incidence of cancer (about 1.8 million new cases annually in the U.S. alone), sophisticated healthcare infrastructure valued at $4.1 trillion, and significant investments in research and development (estimated at $195 billion for healthcare R&D in 2020), North America is expected to lead the CIPN market.

The region's advantageous reimbursement policies, which cover up to 80% of CIPN treatment costs, along with growing awareness of the role supportive care plays in cancer therapy—72% of oncologists now routinely screen for CIPN—help to drive market expansion. Insurance claims relating to CIPNs have increased by 15% in the last year. A novel neuroprotective medication has been granted CIPN Breakthrough Therapy Designation by the U.S. FDA, which could shorten the time to market by three years and demonstrate the region's dedication to addressing this unmet medical need. Based on Phase II clinical trials that demonstrated a 40% decrease in CIPN incidence among high-risk patients, this classification was made. About 80% of the CIPN market in North America is accounted for by the United States, where 630,000 cancer patients are thought to receive CIPN each year.

 

Competitive Intelligence

Strong rivalry among significant players defines the CIPN market and stresses the growth of innovative ideas and increasing range of products. Big pharmaceutical companies are significantly supporting research and development to meet the high unmet need in CIPN treatment. Strategic alliances and licencing agreements are quite common as companies aim to apply complimentary knowledge and technology. Market leaders also pay close attention to regional development and strengthening of their distribution systems in order to have a competitive edge.

 

Major Players

  • Pfizer Inc.

  • Eli Lilly and Company

  • Novartis AG

  • Johnson & Johnson

  • Sanofi S.A.

  • GlaxoSmithKline plc

  • Merck & Co., Inc.

  • Roche Holding AG

  • AstraZeneca plc

  • Bristol-Myers Squibb Company

 

Key Developments

  • Starting a Phase III clinical research for a new neuroprotective drug aiming at CIPN in breast cancer patients in 2023, Pfizer Inc.

  • In 2024 Eli Lilly and Company declared a strategic alliance with a biotech company to create AI-driven solutions for early CIPN identification and tailored treatment choices.

 

Analyst Opinion: 

Driven by the increasing cancer incidence and emphasis on improving quality of life for cancer survivors, the Chemotherapy Induced Peripheral Neuropathy market has great opportunities. Still, it is tough developing targeted, effective treatments for this complex condition. The market is most likely going to shift in the next years toward customized medical approaches and combination therapy.

Exclusive Trend: 

Particularly appealing non-pharmacological treatments for CIPN management are cryotherapy, exercise therapy, and acupuncture. These alternative approaches, which provide possible lower side effects and improved control of symptoms, are growingly popular as complements to conventional treatments.

 

Table of Content

1. INTRODUCTION

   1.1. Market Definitions & Study Assumptions

   1.2. Market Research Scope & Segment  

   1.3. Research Methodology

2. EXECUTIVE SUMMARY

   2.1. Market Overview & Insights

   2.2. Segment Outlook

   2.3. Region Outlook

3. COMPETITIVE INTELLIGENCE

   3.1. Companies Financial Position

   3.2. Company Benchmarking – Key Players

   3.3. Market Share Analysis – Key Companies

   3.4. Recent Companies Key Activities

   3.5. Pricing Analysis

   3.6. SWOT Analysis

4. COMPANY PROFILES (Key Companies list by Country)

5. COMPANY PROFILES

   5.1. Pfizer Inc.

   5.2. Eli Lilly and Company

   5.3. Novartis AG

   5.4. Johnson & Johnson

   5.5. Sanofi S.A.

   5.6. GlaxoSmithKline plc

   5.7. Merck & Co., Inc.

   5.8. Roche Holding AG

   5.9. AstraZeneca plc

   5.10. Bristol-Myers Squibb Company

   5.11. Bayer AG

   5.12. Takeda Pharmaceutical Company Limited

6. MARKET DYNAMICS

   6.1. Market Trends

      6.1.1. Increasing prevalence of cancer and chemotherapy treatments

      6.1.2. Growing research into neuroprotective agents

      6.1.3. Rising adoption of combination therapies

   6.2. Market Drivers

      6.2.1. High unmet need for effective CIPN treatments

      6.2.2. Advancements in drug delivery technologies

      6.2.3. Increasing healthcare expenditure

   6.3. Market Restraints

      6.3.1. Limited efficacy of current treatment options

      6.3.2. High cost of novel therapies

   6.4. Porter's Five Forces Analysis

      6.4.1. Threat of New Entrants

      6.4.2. Bargaining Power of Buyers/Consumers

      6.4.3. Bargaining Power of Suppliers

      6.4.4. Threat of Substitute Products

      6.4.5. Intensity of Competitive Rivalry

   6.5. Supply Chain Analysis

   6.6. Value Chain Analysis

   6.7. Trade Analysis

   6.8. Pricing Analysis

   6.9. Regulatory Analysis

   6.10. Patent Analysis

   6.11. SWOT Analysis

   6.12. PESTLE Analysis

   6.13. Market Opportunities

7. BY DRUG CLASS (MARKET VALUE (US$ MILLION) – 2025-2032*)

   7.1. Antidepressants

      7.1.1. Tricyclic Antidepressants

      7.1.2. Serotonin-Norepinephrine Reuptake Inhibitors

   7.2. Anticonvulsants

      7.2.1. Gabapentin

      7.2.2. Pregabalin

   7.3. Opioids

      7.3.1. Tramadol

      7.3.2. Tapentadol

   7.4. Others

      7.4.1. Topical Analgesics

      7.4.2. Neuroprotective Agents

8. BY INDICATION

   8.1. Platinum-based Agents

      8.1.1. Cisplatin

      8.1.2. Oxaliplatin

   8.2. Taxanes

      8.2.1. Paclitaxel

      8.2.2. Docetaxel

   8.3. Vinca Alkaloids

      8.3.1. Vincristine

      8.3.2. Vinblastine

   8.4. Others

      8.4.1. Bortezomib

      8.4.2. Thalidomide

9. BY DISTRIBUTION CHANNEL

   9.1. Hospital Pharmacies

      9.1.1. Inpatient Pharmacies

      9.1.2. Outpatient Pharmacies

   9.2. Retail Pharmacies

      9.2.1. Chain Pharmacies

      9.2.2. Independent Pharmacies

   9.3. Online Pharmacies

      9.3.1. E-commerce Platforms

      9.3.2. Telemedicine Services

10. BY END-USER

    10.1. Hospitals

       10.1.1. Cancer Centers

       10.1.2. General Hospitals

    10.2. Specialty Clinics

       10.2.1. Oncology Clinics

       10.2.2. Neurology Clinics

    10.3. Homecare Settings

       10.3.1. Home Health Agencies

       10.3.2. Self-administration

11. REGION

    11.1. North America

       11.1.1. United States

       11.1.2. Canada

       11.1.3. Mexico

    11.2. South America

       11.2.1. Brazil

       11.2.2. Argentina

       11.2.3. Rest of South America

    11.3. Europe

       11.3.1. Germany

       11.3.2. United Kingdom

       11.3.3. France

       11.3.4. Italy

       11.3.5. Spain

       11.3.6. Russia

       11.3.7. Rest of Europe

    11.4. Asia-Pacific

       11.4.1. China

       11.4.2. Japan

       11.4.3. India

       11.4.4. Australia

       11.4.5. South Korea

       11.4.6. Rest of Asia-Pacific

    11.5. Middle-East

       11.5.1. UAE

       11.5.2. Saudi Arabia

       11.5.3. Turkey

       11.5.4. Rest of Middle East

    11.6. Africa

       11.6.1. South Africa

       11.6.2. Egypt

       11.6.3. Rest of Africa

Scope of the Report

By Drug Class:

  • Antidepressants

  • Anticonvulsants

  • Opioids

  • Others

By Indication:

  • Platinum-based Agents

  • Taxanes

  • Vinca Alkaloids

  • Others

By Distribution Channel:

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

By End-User:

  • Hospitals

  • Specialty Clinics

  • Homecare Settings

By Region:

  • North America

  • Europe

  • Asia-Pacific

  • Latin America

  • Middle East & Africa

Frequently Asked Questions

We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.

At aurorawaveintellects.com, we believe that every industry is important to us. Our extensive team of analysts give equal focus to various industries in order to cater to our client needs, some of them being – Healthcare & Pharma, Medical, Automotive, Electric, Chemical, Manufacturing, Energy & Power, Consumer Goods etc.
Our core expertise lies in gaining deeper insights from reliable and trusted voices in the market. We always analyse market trends over the course of multiple years and examine which topics are most relevant to our clients. We pay a great deal of attention to emerging trends, niche technologies, and the latest innovations and research to bring out the best that we can offer.
We understand that every client is different and so is their requirement. While we try to gauge our clients’ needs, we are unable to cover every possible angle of a market in an off-the-shelf report. Hence, we also provide customization options to our reports to suit your needs. If you would like to know what information we can provide about a particular topic, please get in touch with us at info@aurorawaveintellects.com.
Our Research Reports give insights into a gamut of qualitative and quantitative topics. Every Research Report contains the following: • Market landscape • Market size • Market segmentation • Market drivers, challenges, and trends • Vendor landscape For more detail on what a specific report contains, click on report details to know more. If you would like to know what information we can provide about a particular topic, please get in touch with us at info@aurorawaveintellects.com
Our Research Reports are frequently updated with new data and predictions. We also have reports from previous years for specific topics. If you need help, contact us at info@aurorawaveintellects.com and we will be happy to assist you for your query.

We at aurorawaveintellects.com offer mainly 3 types of licenses:

• Single User: Research Report copy can be distributed to a single user only

• Multi User: Research Report distribution is restricted up to 5 users.

• Corporate License :Research Report can be distributed across the company.

Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:

• PDF

• Word Document

• PPT

To purchase a research report, you can browse through various categories, industries or topics and choose a particular report. Next, choose a license type and add the report to your cart. Then simply check out and complete the payment transaction and your report will be delivered to your inbox via email..

Following modes are available for making the payment:

• Online Payment (Visa Card, Master Card, Stripe)

• Razorpay

• Net Banking

• Bank Wire Transfer

At Research Reports Inc., we believe in providing the best value and offering competitive pricing to our customers to reflect that value. However, if you would still like to find out about discounts and offers, please get in touch with us at info@aurorawaveintellects.com.
Yes, you can purchase individual sections of the report. Please get in touch with us at info@aurorawaveintellects.com with your specific request, and we will support you accordingly.
As soon as the purchase process is over and the payment transaction is complete, you will receive the receipt via email.
The purchased Research Report is delivered to your registered email address within 48 hours of receipt of payment. If in case you did not, please check your spam folder. If you still haven’t received it, please get in touch with us at info@aurorawaveintellects.com
If you would like to receive a hard copy of the report, please get in touch with us at info@aurorawaveintellects.com with details about your purchase and we will process the same.
At aurorawaveintellects.com, we offer strong after-sales support with every purchase. Feel free to call us or email us with your queries and we will ensure they are addressed appropriately.
The Research Reports we provide are designed to cater to all market participants across the value chain. However, we do understand that every report may or may not meet the exact client requirement. For any specific change or customization in the report, please get in touch with us at info@aurorawaveintellects.com with your specific request, and we will support you accordingly.

Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:

• Email: info@aurorawaveintellects.com

• United Kingdom: ++91 7382742511